S0947000
Somatropin
European Pharmacopoeia (EP) Reference Standard
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Qualité
pharmaceutical primary standard
Famille d'API
somatropin
Fabricant/nom de marque
EDQM
Application(s)
pharmaceutical (small molecule)
Format
neat
Température de stockage
−20°C
Vous recherchez des produits similaires ? Visite Guide de comparaison des produits
Description générale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Somatropin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Conditionnement
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Autres remarques
Sales restrictions may apply.
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Choose from one of the most recent versions:
Certificats d'analyse (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Marianne Klose et al.
The Journal of clinical endocrinology and metabolism, 99(1), 101-110 (2013-11-19)
Recent international guidelines suggest pituitary screening in patients with moderate and severe traumatic brain injury (TBI). Predominantly isolated GH deficiency (GHD) was reported in the literature, raising the question of potential methodological bias. Our objective was to assess the prevalence
Editor's commentary: sex hormone priming.
Zvi Laron
Pediatric endocrinology reviews : PER, 11(3), 288-288 (2014-04-11)
Z Gucev et al.
Pediatric endocrinology reviews : PER, 11(3), 337-338 (2014-04-11)
The Second meeting on Rare Diseases in South Eastern Europe (SEE) was held in Skope, Macedonia on November 15-16, 2013. Objective and main data: Rare diseases (RD) are a major problem in developed and especially in countries without affluence. 6-8%
Long-acting growth hormone.
Charlotte Höybye et al.
Paediatric drugs, 15(6), 427-429 (2013-11-20)
Vita Birzniece et al.
European journal of endocrinology, 170(3), 375-383 (2013-12-19)
GH action is attenuated by estrogens and selective estrogen receptor modulators (SERMs) administered orally. During GH therapy in hypopituitary women, co-treatment with raloxifene, a SERM, induced a smaller gain in lean body mass (LBM) compared with estrogen, despite an equal
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique